Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus Q1 2026 revenue rises 39% to $207.7 million; net loss narrows

Positive Impact 3 of 5 earnings Written later

Supernus reported first quarter 2026 total revenues of $207.7 million, up 39% from $149.8 million a year earlier, and a net loss of $2.3 million, or $0.04 per share, compared with a net loss of $11.8 million, or $0.21 per share, in the prior-year quarter. The company reiterated its full year 2026 financial guidance.

Key points

  • Total revenues were $207.7 million, up 39% year over year, including a $20.0 million licensing milestone from Shionogi.
  • Net loss narrowed to $2.3 million ($0.04 per share) from $11.8 million ($0.21 per share) a year earlier.
  • Full year 2026 guidance was reiterated, with total revenues of $840 million to $870 million and GAAP operating earnings of $0 to $30 million, as of February 24, 2026.

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECMay 5, 2026, 4:09 PM ET
Accession number0001356576-26-000020

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.